SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report)’s share price fell 4.8% during trading on Monday . The company traded as low as $14.03 and last traded at $14.2650. Approximately 4,612,166 shares were traded during trading, a decline of 46% from the average session volume of 8,562,639 shares. The stock had previously closed at $14.98.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the stock. Maxim Group lifted their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, SELLAS Life Sciences Group presently has an average rating of “Hold” and an average price target of $10.00.
View Our Latest Stock Analysis on SLS
SELLAS Life Sciences Group Stock Down 8.1%
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.
Institutional Investors Weigh In On SELLAS Life Sciences Group
Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its stake in shares of SELLAS Life Sciences Group by 535.7% during the first quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock valued at $2,714,000 after purchasing an additional 540,748 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after purchasing an additional 1,709 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of SELLAS Life Sciences Group by 20.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 45,691 shares of the company’s stock worth $193,000 after buying an additional 7,673 shares during the last quarter. Quantinno Capital Management LP purchased a new stake in shares of SELLAS Life Sciences Group in the 1st quarter worth approximately $315,000. Finally, Independent Financial Group LLC bought a new position in SELLAS Life Sciences Group during the 1st quarter valued at approximately $98,000. Institutional investors own 17.38% of the company’s stock.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.
The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.
Read More
- Five stocks we like better than SELLAS Life Sciences Group
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
